Amanda Betancourt-Cortez, PA
Medical · San Antonio, TXNPI 1245689876
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 42.4% of the total. Reporting peaked in 2021 at $1,246 and has fallen 87.6% since, to $155 in 2024.
Across 59 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$794
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$389
- Gilead$232
- Johnson & Johnson$177
- Medical Device Business Services, Inc.$97
- Eisai Inc.$42
- plus $141 from 6 others
What the payments were for
- Speaking & faculty fees$71438%
- Food & beverage$1,06057%
- Education$985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $794 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $389 |
| Gilead | 14 | $232 |
| Johnson & Johnson | 6 | $177 |
| Medical Device Business Services, Inc. | 2 | $97 |
| Eisai Inc. | 2 | $42 |
| Merck | 2 | $35 |
| Boehringer Ingelheim | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
How this compares
$1,872 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 185 | $3,036 |
| Diclofenac Sodium | 24 | $703 |
| Tramadol Hcl | 80 | $284 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 29 | $172 |
| Cyclobenzaprine Hcl | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Other medical in San Antonio
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
- John KodoskySan Antonio$58K
- Amanda MillerSan Antonio$27K
- Felipe GalvanSan Antonio$26K
- Ledyenska BallesterosSan Antonio$22K
- Daniella ArellanoSan Antonio$15K
- Robert SchonhoffSan Antonio$14K
- Tanya GainesSan Antonio$14K
- Ivanna SaucedoSan Antonio$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.